文献速递心律失常

心血管临床试验数据共享的可行性:SMART-AF试验的再现分析

Feasibility, Process, and Outcomes of Cardiovascular Clinical Trial Data Sharing: A Reproduction Analysis of the SMART-AF Trial.
PubMed 文献 · JAMA Cardiol · 2017-01-01

本研究通过耶鲁开放数据获取项目获取SMART-AF试验的共享数据,对这项多中心单臂试验进行再现分析。结果显示12个月无房性心律失常率与原文相似,但再现分析成功率高于原文报告,且接触力范围或回归模型无法再现。数据共享的可行性得到证实。

要点

  • 通过学术数据共享平台可获取原始试验数据集并完成再现分析。
  • 再现分析无房性心律失常率与原文相似,但成功率高于原文。
  • 接触力范围或回归模型无法从共享数据中再现。

核心结论

  • 通过学术数据共享平台对SMART-AF试验进行再现分析是可行的。

研究设计与样本

  • SMART-AF为多中心单臂试验,纳入172例药物难治性症状性阵发性房颤患者,来自21个中心,2011年6月至12月入组。
  • 再现分析使用通过耶鲁开放数据获取项目及SAS临床试验数据透明平台获取的数据集、数据字典、病例报告表和统计分析计划。
  • 数据分析于2016年12月至2017年4月进行。

主要发现

  • 参与者平均年龄58.7(10.8)岁,72%为男性。
  • 从初始提案提交到最终分析的时间为11个月。
  • 术后12个月无房性心律失常率与主要研究报告相似:74.0%(95%CI 66.0-82.0)vs 76.4%(95%CI 68.7-84.1)。
  • 再现分析成功率高于主要研究报告:65.8%(95%CI 56.5-74.2)vs 75.6%(95%CI 67.2-82.5)。
  • 不良事件极少且两项分析间相似,但接触力范围或回归模型无法再现。

临床怎么用

  • 数据共享可通过激励协作、共享统计代码和建立限制更少的去中心化数据共享平台来促进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Data sharing is as an expanding initiative for enhancing trust in the clinical research enterprise. OBJECTIVE: To evaluate the feasibility, process, and outcomes of a reproduction analysis of the THERMOCOOL SMARTTOUCH Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (SMART-AF) trial using shared clinical trial data. DESIGN, SETTING, AND PARTICIPANTS: A reproduction analysis of the SMART-AF trial was performed using the data sets, data dictionary, case report file, and statistical analysis plan from the original trial accessed through the Yale Open Data Access Project using the SAS Clinical Trials Data Transparency platform. SMART-AF was a multicenter, single-arm trial evaluating the effectiveness and safety of an irrigated, contact force-sensing catheter for ablation of drug refractory, symptomatic paroxysmal atrial fibrillation in 172 participants recruited from 21 sites between June 2011 and December 2011. Analysis of the data was conducted between December 2016 and April 2017. MAIN OUTCOMES AND MEASURES: Effectiveness outcomes included freedom from atrial arrhythmias after ablation and proportion of participants without any arrhythmia recurrence over the 12 months of follow-up after a 3-month blanking period. Safety outcomes included major adverse device- or procedure-related events. RESULTS: The SMART AF trial participants' mean age was 58.7 (10.8) years, and 72% were men. The time from initial proposal submission to final analysis was 11 months. Freedom from atrial arrhythmias at 12 months postprocedure was similar compared with the primary study report (74.0%; 95% CI, 66.0-82.0 vs 76.4%; 95% CI, 68.7-84.1). The reproduction analysis success rate was higher than the primary study report (65.8%; 95% CI 56.5-74.2 vs 75.6%; 95% CI, 67.2-82.5). Adverse events were minimal and similar between the 2 analyses, but contact force range or regression models could not be reproduced. CONCLUSIONS AND RELEVANCE: The feasibility of a reproduction analysis of the SMART-AF trial was demonstrated through an academic data-sharing platform. Data sharing can be facilitated through incentivizing collaboration, sharing statistical code, and creating more decentralized data sharing platforms with fewer restrictions to data access.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Gay HC, Baldridge AS, Huffman MD, et al. Feasibility, Process, and Outcomes of Cardiovascular Clinical Trial Data Sharing: A Reproduction Analysis of the SMART-AF Trial. JAMA Cardiol. 2017. PMID: 29049540. doi:10.1001/jamacardio.2017.3808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。